FindTrial
Sign In

A Clinical Study To Find Which Homoeopathic Medicine Either Gelsemium Sempervirens Or Phosphoricum Acidum Are Most Effective In Cases Of Post Viral Fatigue Having Symptoms Such As Persistent, Debilitating Exhaustion That Lingers After A Viral Infection.

A Clinical Comparative Study Of Gelsemium Sempervirens And Phosphoricum Acidum In Cases Of Post Viral Fatigue Among 30 To 50 Years Of Age Group Using The Fatigue Severity Scale. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/102010
Enrollment
30
Registered
2026-01-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G933- Postviral fatigue syndrome

Interventions

Intervention1: GELSEMIUM SEMPERVIRENS 30C: Patients With Post-Viral Fatigue Attending Opd Will Be Selected For The Study On The Basis Of Case Taking. Detailed Case Taking Will Be Done As Per Performa

Sponsors

PARUL INSTITUTE OF HOMOEOPATHY AND RESEARCH
Lead Sponsor
ROHINI MADHUBHAI SANGANI
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patient Already Diagnosed With Post Viral Fatigue. All Socio-Economic Status.

Exclusion criteria

Exclusion criteria: Fatigue Due To Another Medical Condition. Patient Already On Other Medication. Pregnant Or Lactating Woman.

Design outcomes

Primary

MeasureTime frame
To Compare The Utility And Outcomes Between Gelsemium Sempervirens 30C And Phosphoricum Acidum 30C.Timepoint: 3 MONTHS—

Secondary

MeasureTime frame
To Assess General Well-Being & Quality Of Life Improvements Using The Fatigue Severity ScaleTimepoint: 3 MONTHS—

Countries

India

Contacts

Public ContactROHINI MADHUBHAI SANGANI

Parul Institute of Homoeopathy and Research and Hospital

dipika.sindha87141@paruluniversity.ac.in9978919488

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026